% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sasamoto:143813,
      author       = {N. Sasamoto and A. Babic and B. A. Rosner and R.
                      Turzanski-Fortner$^*$ and A. F. Vitonis and H. Yamamoto and
                      R. N. Fichorova and A. Tjønneland and L. Hansen and K.
                      Overvad and M. Kvaskoff and A. Fournier and F. Romana
                      Mancini and H. Boeing and A. Trichopoulou and E. Peppa and
                      A. Karakatsani and D. Palli and V. Pala and A. Mattiello and
                      R. Tumino and C. C. Grasso and N. C. Onland-Moret and E.
                      Weiderpass and J. R. Quirós and L. Lujan-Barroso and M.
                      Rodríguez-Barranco and S. Colorado-Yohar and A. Barricarte
                      and M. Dorronsoro and A. Idahl and E. Lundin and H. Sartor
                      and K.-T. Khaw and T. J. Key and D. Muller and E. Riboli and
                      M. J. Gunter and L. Dossus and R. Kaaks$^*$ and D. W. Cramer
                      and S. S. Tworoger and K. L. Terry},
      title        = {{P}redicting {C}irculating {CA}125 {L}evels among {H}ealthy
                      {P}remenopausal {W}omen.},
      journal      = {Cancer epidemiology, biomarkers $\&$ prevention},
      volume       = {28},
      number       = {6},
      issn         = {1538-7755},
      address      = {Philadelphia, Pa.},
      publisher    = {AACR},
      reportid     = {DKFZ-2019-01375},
      pages        = {1076 - 1085},
      year         = {2019},
      abstract     = {Background: Cancer antigen 125 (CA125) is the most
                      promising ovarian cancer screening biomarker to date.
                      Multiple studies reported CA125 levels vary by personal
                      characteristics, which could inform personalized CA125
                      thresholds. However, this has not been well described in
                      premenopausal women.Methods: We evaluated predictors of
                      CA125 levels among 815 premenopausal women from the New
                      England Case Control Study (NEC). We developed linear and
                      dichotomous (≥35 U/mL) CA125 prediction models and
                      externally validated an abridged model restricting to
                      available predictors among 473 premenopausal women in the
                      European Prospective Investigation into Cancer and Nutrition
                      Study (EPIC).Results: The final linear CA125 prediction
                      model included age, race, tubal ligation, endometriosis,
                      menstrual phase at blood draw, and fibroids, which explained
                      $7\%$ of the total variance of CA125. The correlation
                      between observed and predicted CA125 levels based on the
                      abridged model (including age, race, and menstrual phase at
                      blood draw) had similar correlation coefficients in NEC (r =
                      0.22) and in EPIC (r = 0.22). The dichotomous CA125
                      prediction model included age, tubal ligation,
                      endometriosis, prior personal cancer diagnosis, family
                      history of ovarian cancer, number of miscarriages, menstrual
                      phase at blood draw, and smoking status with AUC of 0.83.
                      The abridged dichotomous model (including age, number of
                      miscarriages, menstrual phase at blood draw, and smoking
                      status) showed similar AUCs in NEC (0.73) and in EPIC
                      (0.78).Conclusions: We identified a combination of factors
                      associated with CA125 levels in premenopausal women.Impact:
                      Our model could be valuable in identifying healthy women
                      likely to have elevated CA125 and consequently improve its
                      specificity for ovarian cancer screening.},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30948451},
      doi          = {10.1158/1055-9965.EPI-18-1120},
      url          = {https://inrepo02.dkfz.de/record/143813},
}